Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | CTSK | P43235 | 3/20 | 0.45 |
| ▸ | CTSL | P07711 | 2/20 | 0.45 |
| ▸ | CTSS | P25774 | 2/20 | 0.45 |
| ▸ | CTSB | P07858 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13617288 | 1.00 | CA1 (0.46) | CA1CA2CA7CTSKCTSL | |
| SCHEMBL6791378 | 1.00 | CA1 (0.46) | CA1CA2CA7CTSKCTSL | |
| SCHEMBL28953786 | 1.00 | CA1 (0.46) | CA1CA2CA7CTSKCTSL | |
| SCHEMBL8270799 | 1.00 | CA1 (0.46) | CA1CA2CA7CTSKCTSL | |
| SCHEMBL13694102 | 1.00 | CA1 (0.46) | CA1CA2CA7CTSKCTSL | |
| SCHEMBL21012512 | 0.86 | CA1 (0.39) | CA1CA2CA7CTSKCTSL | |
| SCHEMBL11025437 | 0.84 | CA1 (0.41) | CA1CA2CA7CTSKCTSS | |
| SCHEMBL590056 | 0.84 | CTSK (0.42) | CA1CA2CA7CTSKCTSS | |
| SCHEMBL3327360 | 0.82 | CA1 (0.40) | CA1CA2CA7CTSKCTSS | |
| SCHEMBL28848464 | 0.81 | CTSK (0.50) | CA1CA2CA7CTSKCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114957053-B | Oxoethylene compound or pharmaceutically acceptable salt thereof, preparation method and application thereof, pharmaceutical composition and application thereof | 中国医学科学院医药生物技术研究所 | 2023-12-22 | — | — | CN | disclosed |
| WO-2010107384-A1 | ASPARTYL PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2010-09-23 | — | — | WO | disclosed |
| EP-1773758-A1 | OXIME DERIVATIVE HYDROXYETHYLAMINE ASPARTYL-PROTEASE INHIBITORS | Elan Pharmaceuticals, Inc. (US) | 2007-04-18 | — | — | EP | disclosed |
| US-20060128715-A1 | Oxime derivative hydroxyethylamine aspartyl-protease inhibitors | ELAN PHARMACEUTICALS, INC. | 2006-06-15 | — | — | US | disclosed |
| WO-2006010094-A1 | OXIME DERIVATIVE HYDROXYETHYLAMINE ASPARTYL-PROTEASE INHIBITORS | ELAN PHARMACEUTICALS, INC. (US) | 2006-01-26 | — | — | WO | disclosed |
| EP-0975588-A1 | ANTIPICORNAVIRAL COMPOUDS, COMPOSITIONS CONTAINING THEM, AND METHODS FOR THEIR USE | AGOURON PHARMACEUTICALS, INC. (US) | 2000-02-02 | — | — | EP | disclosed |
| WO-1998043950-A1 | ANTIPICORNAVIRAL COMPOUDS, COMPOSITIONS CONTAINING THEM, AND METHODS FOR THEIR USE | AGOURON PHARMACEUTICALS, INC. (US) | 1998-10-08 | — | — | WO | disclosed |
| US-5346887-A | Mixture of tripeptide renin inhibitor and steroid antiinflammatory agent | ABBOTT LABORATORIES (US) | 1994-09-13 | — | — | US | disclosed |
| US-5059589-A | Glaucoma treatment | ABBOTT LABORATORIES (US) | 1991-10-22 | — | — | US | disclosed |
| US-5036051-A | Renin inhibitors | ABBOTT LABORATORIES (US) | 1991-07-30 | — | — | US | disclosed |
| EP-0258289-A4 | PEPTIDE ANALOGS | — | 1991-01-02 | — | — | EP | disclosed |
| US-4927807-A | RENIN INHIBITING AMIDES | ABBOTT LABORATORIES (US) | 1990-05-22 | — | — | US | disclosed |
| US-4857507-A | HYPOTENSIVE AGENT | ABBOTT LABORATORIES (US) | 1989-08-15 | — | — | US | disclosed |
| US-4826815-A | HYPOTENSIVE | ABBOTT LABORATORIES (US) | 1989-05-02 | — | — | US | disclosed |
| EP-0311012-A2 | Glaucoma treatment | ABBOTT LABORATORIES (US) | 1989-04-12 | — | — | EP | disclosed |
| EP-0258289-A1 | PEPTIDE ANALOGS | ABBOTT LABORATORIES (US) | 1988-03-09 | — | — | EP | disclosed |
| WO-1987004349-A1 | PEPTIDE ANALOGS | DELLARIA JOSEPH | 1987-07-30 | — | — | WO | disclosed |
| US-4645759-A | HYPOTENSIVE AGENTS | ABBOTT LABORATORIES (US) | 1987-02-24 | — | — | US | disclosed |
| EP-0172347-A2 | Renin inhibiting compounds | ABBOTT LABORATORIES (US) | 1986-02-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128715-A1 | Oxime derivative hydroxyethylamine aspartyl-protease inhibitors | ASPH, DNPEP, APP | CA1 592/4885CA2 1642/4885CA7 1938/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.